LITTLE GREEN PHARMA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.095 AUD | -9.52% |
|
-5.00% | -32.14% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.14% | 19.13M | - | ||
| +26.93% | 5.55B | B- | ||
| -33.55% | 3.52B | C+ | ||
| -3.74% | 3.03B | C | ||
| -26.09% | 2.59B | B- | ||
| -10.93% | 2.28B | - | D+ | |
| +41.50% | 1.88B | - | ||
| +41.84% | 1.46B | - | ||
| -12.94% | 1.43B | - | - | |
| +47.62% | 1.42B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LGP Stock
- Ratings Little Green Pharma Ltd
